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Abstract
Background: Even if genetics play an important role, individual variation in stature remains unexplained at the
molecular level. Indeed, genome-wide association study (GWAS) have revealed hundreds of variants that contribute
to the variability of height but could explain only a limited part of it, and no single variant accounts for more than
0.3% of height variance. At the interface of genetics and environment, epigenetics contributes to phenotypic
diversity. Quantifying the impact of epigenetic variation on quantitative traits, an emerging challenge in humans,
has not been attempted for height. Since insulin-like growth factor 1 (IGF1) controls postnatal growth, we tested
whether the CG methylation of the two promoters (P1 and P2) of the IGF1 gene is a potential epigenetic
contributor to the individual variation in circulating IGF1 and stature in growing children.
Results: Child height was closely correlated with serum IGF1. The methylation of a cluster of six CGs located within the
proximal part of the IGF1 P2 promoter showed a strong negative association with serum IGF1 and growth. The highest
association was for CG-137 methylation, which contributed 13% to the variance of height and 10% to serum IGF1. CG
methylation (studied in children undergoing surgery) was approximately 50% lower in liver and growth plates, indicating
that the IGF1 promoters are tissue-differentially methylated regions (t-DMR). CG methylation was inversely correlated with
the transcriptional activity of the P2 promoter in mononuclear blood cells and in transfection experiments, suggesting
that the observed association of methylation with the studied traits reflects true biological causality.
Conclusions: Our observations introduce epigenetics among the individual determinants of child growth and serum
IGF1. The P2 promoter of the IGF1 gene is the first epigenetic quantitative trait locus (QTLepi) reported in humans. The CG
methylation of the P2 promoter takes place among the multifactorial factors explaining the variation in human stature.
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Background
Although defined as a variant of normal, ‘idiopathic’
short stature in a child is a common source of medical
investigation and a potential indication for treatment
with growth hormone [1]. The molecular causes of idio-
pathic short stature are multiple [2], as expected for a
multifactorial trait that is influenced both by individual
genotypes and environmental factors [3].
First studied by F. Galton at the end of the nineteenth
century [4], height heritability and variability remain
partially understood [5,6]. Twin and family studies have
consistently estimated that the additive genetic contribu-
tion to normal variation in adult height approximates
80% in a given population at a given time [7-9]. As pre-
dicted by R.A Fisher [7], the genetic heritability of height
is explained by many variants of individually small effect.
A recent genome-wide association study (GWAS) study
identified variants at 180 loci that together explain
approximately 12% of the heritable variation in height
[10]. Another GWAS suggested that half of the heritabil-
ity of height can be accounted for by additive effects of a
large number of common variants [11]. The most recent
meta-analysis using the summary statistics from 79 studies
totalling 253,288 individuals of European ancestry showed
that the most strongly associated 2,000, 3,700, and 9,500
SNPs account for 21%, 24%, and 29% of height variance,
respectively [9]. No single variant identified in these
GWAS explained more than 0.3% of height variance.
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Genetics thus seems to explain a major but limited part of
height variability across individuals.
Classically, quantitative geneticists envision DNA se-
quence variants as the only source of heritable pheno-
types. This view should be revised in light of accumulating
evidence for widespread epigenetic variation in natural
populations [12,13]. Indeed, the current sequence-based
quantitative trait locus (QTL) approaches for dissecting
complex traits miss important phenotypic effects exerted
by epigenetic variants [13]. While epigenetics is a consid-
erable source of inherited and acquired variability among
humans [14], its contribution to height variability has not
been studied.
To explore the individual variability of child growth and
search for new causes of short stature, we selected the insu-
lin-like growth factor 1 (IGF1) gene as a prominent physio-
logical candidate. IGF1 is a key player in postnatal growth
and GH signaling. Inactivating mutations in the IGF1 gene
alter postnatal growth in humans [15] and mice [16]. Clin-
ical studies show a strong correlation between height and
circulating IGF1 in childhood [17], and IGF1 production
disorders are a source of short stature [18]. However, com-
mon genetic variation in the IGF1 gene sequence does not
contribute significantly to adult height variation in popula-
tions of Caucasians [19,20] while it does so in Asians
whose IGF1 allele frequency is different [21,22].
Twin studies indicate that the genetically determined
proportion of circulating IGF1 variance ranges between
38% and 80% [23-25]. The association of circulating
IGF1 with several genetic variants is debated [26-28],
but variants at the IGF1 locus do not seem to influence
circulating IGF1 in Caucasian adults [26,29] except,
maybe, the commonest Z allele of the microsatellite lo-
cated 1 kb upstream of the IGF1 gene [19,30]. Overall, the
genetic basis for serum IGF1 variability remains unknown
in adults and has not been studied in growing children.
Most epigenetic effects on phenotypes result from effects
on gene expression, particularly for the methylation of CG
located within gene promoters. Our hypothesis was that
variation in epigenetic marks located in the promoters that
regulate IGF1 gene expression [31] might play a role in
modulating IGF1 gene expression, thus contribute to the
individual variation of IGF1 production and child growth.
In addition, these promoters are CG-poor and expected to
exhibit inter-individual variation [32]. Instead of using a
whole-methylome array to test associations with height or
serum IGF1, our candidate gene approach enabled us to
quantify the methylation of each CG of the IGF1 pro-
moters accurately. Indeed, an individual CG may have a
significant functional role different from its CG neighbors
[33,34], and this effect cannot be unraveled if the specific
CG is not part of the commercial array. In addition, quan-
tifying the methylation of each CG provides a mean to test
its correlation with height or circulating IGF1.
Among the various categories of IGF1 transcripts, class
I transcripts have their initiation sites on exon 1 and are
driven by P1 promoter, while class II transcripts use exon
2 as a leader exon and are driven by P2 promoter [35,36].
IGF1 transcripts initiating at P1 are constitutively expressed
in many tissues, transcripts initiating at P2 are expressed
primarily but not exclusively in the liver [31,37].
The current study explores the relation between the
methylation of the CGs located within IGF1 gene pro-
moters and child height and circulating IGF1 and tests
how promoter methylation affects transcriptional activity
in subjects’ blood cells and in transfected cells.
Results
Patterns of methylation in the two IGF1 gene promoters
The patterns of CG methylation within the two promoters
of IGF1 are depicted in Figure 1. Methylation in the prox-
imal part of P2 promoter showed an important individual
variability (Figure 1 and Additional file 1: Table S2). Strong
intra-promoter correlations (10−8 < P < 10−3) were observed
between methylation of the CGs in P2 promoter, while
there was no correlation within P1 or between CGs of P1
and P2. The methylation at the P2 and P1 promoters
does not seem to be significantly influenced by sex or
age (Additional file 1: Table S3).
Methylation levels were comparable in white blood cells
(WBC), peripheral blood mononuclear cells (PBMC), and
CD4+ T lymphocytes (Figure 2). The methylation levels were
approximately 50% lower for most P1 and P2 CGs in liver
and growth plates than in blood cells (Figure 2, Additional
file 1: Table S4). The IGF1 promoters can thus be consid-
ered as tissue differentially methylated regions (t-DMR).
Height and serum IGF1 are inversely correlated with CG
methylation of the P2 promoter
In the discovery cohort of 110 children (Table 1), height
was found to be inversely correlated with the methylation
of 4/8 CGs of the P2 promoter (10−3 < P < 0.01 after Bonfer-
roni correction) (Table 1). These observations were repli-
cated in a second cohort of 106 children (Table 1). After
merging the two cohorts, the inverse correlation with height
was confirmed for 6/8 CGs of the P2 promoter and was
maximal for CG-137 methylation (P = 4 × 10−7) (Figure 3A
and Table 1), so that CG-137 methylation accounted for
13% of height variability (Figure 3A). Since 6/8 CGs in P2
trend to an association and are physically located very close
together, the average methylation was calculated for these
6 CGs and showed a strong inverse correlation with
height (P = 7 × 10−5) (Table 1) and with only 1/9 CGs
(CG-611) of the P1 promoter (P = 4.2 × 10−7) (Table 1).
Height was closely correlated with serum IGF1 (P =
6 × 10−15) (Figure 3B), so that the variability of circulating
IGF1 accounts for 27% of height variability in the current
cohort. As previously observed for height, strong inverse
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correlations were found between serum IGF1 and the
methylation of 4/8 CGs in the P2 promoter (10−4 < P < 0.01
after Bonferroni correction), notably CG-137 (Figure 3C
and Table 2). CG-137 methylation contributed 10% to
serum IGF1 variation. Again, CG-611 was the only CG of
the P1 promoter to show an inverse correlation with
serum IGF1 (P = 0.009) (Table 2).
Relationship between methylation and genetic variation
at the IGF1 locus
We found no relationship between the common CA re-
peat variant located −822 bp from the P2 transcription
start site (TSS) and methylation of P1 or P2 promoters
(Figure 4) or between this repeat variant and height or
circulating IGF1 (Figure 4).
Figure 1 The two IGF1 gene promoters (P1 and P2) are figured in the lower part of the figure (broken arrows show the TSS of
each promoter). The upper part of the figure shows the methylation level of each studied CG in the 216 children (mean ± SD). The horizontal
black bar encompasses the cluster of six CGs of P2 promoter whose methylation is inversely correlated with height and serum IGF1.
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Figure 2 Tissue-specific methylation levels in white blood cells (WBC), peripheral blood mononuclear cells (PBMC), CD4+ T lymphocytes,
liver, and tibial growth plates. For simplicity, values in only ten patients are figured for WBC and PBMC. The complete set of values is shown in
Additional file 1: Table S4.
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Relationship between methylation and IGF1 transcripts in
children PBMC
Class I transcripts accounted for 73% of the total IGF1
transcripts and class II for the remaining 27% in the
PBMC of the studied children (Figure 5A). Within an
individual, the levels of class I and class II transcripts were
highly correlated (R = 0.66; P = 1.4 × 10−7) (Figure 5B).
Class II transcripts were inversely correlated with
CG-137 methylation (R = −0.67; P = 7 × 10−8) (Figure 5C),
which accounted for 45% of the variation in class II
Table 1 Correlation between the percent methylation of each studied CG and child height (N = 216)
Height (SDS)
Discovery cohort Replication cohort Total
R P R P R P
P1 promoter CG-1044 0.02 1 0.02 1 0.03 1
CG-960 0.05 1 0.06 1 0.06 1
CG-919 0.02 1 −0.13 1 0.04 1
CG-631 −0.04 1 −0.04 1 −0.09 1
CG-611 −0.25 0.1 −0.48 2.2.10−5 −0.39 4.10−7
CG-491 −0.06 1 −0.31 0.03 −0.10 1
CG-414 0.00 1 −0.19 0.4 0.09 1
CG-308 0.02 1 0.02 1 0.00 1
CG-225 0.08 1 0.012 1 −0.10 1
P2 promoter CG-232 −0.08 1 −0.28 0.03 −0.21 0.01
CG-224 −0.32 10−2 −0.17 0.7 −0.24 0.003
CG-218 −0.36 10−3 −0.30 0.02 −0.33 1.2.10−5
CG-207 −0.35 2.10−3 −0.12 1 −0.24 4.10−3
CG-137 −0.30 10−2 −0.40 1.9.10−4 −0.36 4.10−7
CG-108 −0.25 0.10 −0.19 0.5 −0.23 0.12
Average* −0.31 0.007 −0.27 0.004 −0.3 7.10−5
CG-77 −0.09 1 −0.04 1 −0.04 1
CG + 97 −0.08 1 −0.03 1 0.07 1
*Values for the averaged 6 CGs from −108 to −232. To account for multiple CG testing, we used Bonferroni correction of the P values. P values greater than 1 are
equated to 1.
Italicized letters and numbers indicate significant correlation.
(A) (B) (C)
R=-0.36, P=2.3x10-8 R=-0.32, P=6.6x10-6R=0.53, P=6x10-15
Figure 3 CG-137 methylation correlates negatively with height and with serum IGF1. (A) Inverse correlation between CG-137 methylation and
height in studied children (N= 216), (Y=−0.12X + 4.1; R=−0.36, P= 2.3× 10−8). (B) Correlation between circulating IGF1 and height (N= 184), Y= 0.6X− 1
(R= 0.53, P= 6× 10−15). (C) Inverse correlation between CG-137 methylation and serum IGF1 (N= 184), (Y=−0.09X + 3.2; R=−0.32, P= 6.6× 10−6).
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transcripts in PBMC. CG-137 methylation showed only a
weak inverse correlation with class I transcripts (Figure 5D)
and a highly significant correlation with total IGF1 tran-
scripts (Figure 5E).
Artificial demethylation of P2 promoter increases
transcription in a reporter gene assay
To test in vitro whether the methylation of the P2 pro-
moter affects IGF1 gene expression, we used a reporter
gene construct made by inserting a fragment of IGF1 P2
promoter extending from −1,014 to +64 bp of the TSS -
thus containing 7 of the studied CGs - into a promoter-
less CpG-free luciferase expression plasmid. Constructed
plasmid was mock-methylated or methylated with M.
SssI CpG methyltransferase, then transiently transfected
into HEK 293 cells in which basal luciferase gene ex-
pression was measured. Demethylation of the human
IGF1 P2 promoter increased luciferase reporter gene ex-
pression by 57% (Figure 6), indicating that the methyla-
tion status of the P2 promoter is a significant regulator
Table 2 Correlation between methylation of all studied CGs and serum IGF1 concentration (SDS) (N = 184)
Serum IGF1 (SDS)
Discovery cohort Replication cohort Total
R P R P R P
P1 promoter CG-1044 −0.05 1 0.08 1 0.03 1
CG-960 0.08 1 0.07 1 0.01 1
CG-919 0.07 1 −0.22 0.6 −0.10 1
CG-631 −0.18 0.7 −0.07 1 −0.10 1
CG-611 −0.27 0.06 −0.33 0.02 −0.25 9.10-3
CG-491 −0.05 1 −0.11 1 −0.07 1
CG-414 0.06 1 0.21 0.6 −0.15 0.5
CG-308 0.00 1 0.04 1 0.03 1
CG-225 0.09 1 0.09 1 0.04 1
P2 promoter CG-232 −0.19 0.46 −0.29 0.08 −0.24 8.10−3
CG-224 −0.24 0.14 −0.05 1 −0.19 9.10−2
CG-218 −0.23 0.17 −0.22 0.5 −0.24 0.01
CG-207 −0.14 1 0.09 1 −0.14 0.5
CG-137 −0.34 5.10−3 −0.28 0.11 −0.32 10−4
CG-108 −0.29 0.08 −0.28 0.05 −0.30 4.10−4
Average* −0.30 0.017 −0.25 0.17 −0.29 6.10−4
CG-77 −0.23 0.25 −0.09 1 −0.17 0.3
CG + 97 −0.22 0.29 −0.04 1 −0.12 1
To account for multiple CG testing, we used Bonferroni correction of the P values studied. P values greater than 1 are equated to 1. *Values for the averaged 6
CGs from −108 to −232.
Italicized letters and numbers indicate significant correlation.
Figure 4 Lack of relationship between the genotype categories of the microsatellite polymorphism upstream to the IGF1 gene and
height, circulating IGF1 or CG-137 methylation (N = 130).
Ouni et al. Clinical Epigenetics  (2015) 7:22 Page 5 of 12
of transcriptional activity of this promoter in a plasmid
environment devoid of chromatin.
Discussion
Our observations indicate that the methylation of the P2
promoter of IGF1 in PBMC is strongly and negatively
associated with serum IGF1 and child growth. The P2
promoter can thus be considered an epigenetic quantita-
tive trait locus (QTLepi) [13] for these traits. To our know-
ledge, QTLepi have yet been identified only in plants
[12,13]. It is remarkable that P2 promoter methylation
contributes 13% to individual height variance, a much
greater contribution than ‘major’ genetic variants that
account for less than 0.3% each [10,11,20,38-40]. This
underscores the potential quantitative importance of epi-
genetics in the variation of phenotypes.
The molecular causes of idiopathic short stature are
multiple [2], as for any multifactorial trait influenced by
individual genotypes and environmental factors. High
levels of CG methylation at the P2 promoter now appear
as one of the many molecular mechanisms responsible
for ‘idiopathic’ short stature.
(A) (B) (C) 
(D) (E) 
Log of concentration of
basal P1-driven transcripts (ng/ul) 
R=0.66, P=1.4x10-7
R=-0.67, P=2.7x10-3 R=-0.65, P=2.8x10-7
R=-0.67, P=7x10-8
Figure 5 IGF1 transcripts. (A) P1-driven, P2-driven, and total IGF1 transcripts in the PBMC from 49/216 children. (B) Correlation between class I
P1-driven transcripts and class II P2-driven transcripts Y = 0.55X − 2.96 (R = 0.66, P = 1.4 × 10−7). (C) Inverse correlation between CG-137 methylation
and P2-driven transcripts Y = −0.09X − 2.3 (R = −0.67, P = 7 × 10−8). (D) Inverse correlation between CG-137 methylation and P1-driven transcripts
Y = −0.06X − 2.93 (R = −0.67, P = 2.7 × 10−3). (E) Inverse correlation between CG-137 methylation and all IGF1 transcripts Y = −0.09X − 1.6
(R = −0.65, P = 2.8 × 10−7).
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Another potential application of our observation is the
secular increase of height [41]. One could speculate that
IGF1 P2 promoter methylation might be an epigenetic
link between genetic and environmental determinants of
height and contribute to the secular increase in growth
observed in genetically stable populations. Indeed, modi-
fications of DNA methylation patterns can be inherited
trans-generationally, through incomplete erasure of epi-
genetic patterning in the germline. An accumulation of
epigenetic changes through generations would then pro-
vide a valuable, reversible mechanism of adaptation to
progressively changing environments. In this respect, the
known interaction between energy metabolism, body
composition, and IGF1 physiology [42] may stimulate
the research of epigenetic links between evolving nutri-
tional factors and height changes throughout generations.
The mechanisms generating variation of CG methyla-
tion across humans are not known [43], and this lack of
knowledge applies to the individual variations observed
in the CG methylation of the IGF1 P2 promoter. Vari-
ation in methylation can arise through cis [44-46] or
trans genetic effects [47,48] or as a result of stochastic
events, developmental changes, or exposure to environ-
mental cues [49,50]. The variation in DNA methylation
patterns observed in MZ twins suggests that maternal
environment affects the fetal epigenome [49,51].
The inverse correlation of P2 promoter methylation
with both height and circulating IGF1 and the strong
positive correlation between serum IGF1 and height
suggest that the epigenetic effects of P2 methylation on
child growth are mediated by primary effects on IGF1
production. The IGF1 gene is expressed in most, if not
all, tissues of the body, but the liver and the chondro-
cytes of the growth plates are the main regulators of sys-
temic IGF1 production and skeletal growth, respectively.
Mice models have revealed that GH effects on skeletal
growth are mediated by IGF1 produced in situ by chon-
drocytes, not by circulating IGF1 produced by the liver
[52,53]. The close correlation of P2 methylation with cir-
culating IGF1 and height supports that the correlation
between P2 methylation and IGF1 gene expression ob-
served in PBMC has a biological relevance to IGF1 and
growth physiology. However, our observation should be
interpreted with caution because of the lack of data in
growth-related tissues. Given the tissue specificity of cell
epigenomes, the lack of analysis of physiological tissues
and the use of blood cells as surrogates [54,55] are com-
mon but major weaknesses of epigenetic epidemiology
[14,56]. Measurement of CG methylation in liver and
growth plates in a limited number of children undergo-
ing surgical procedures showed that methylation was
much lower in these tissues than in blood cells, indicat-
ing that the P2 and P1 promoters are tissue-specific dif-
ferentially methylated regions (t-DMR). One further
caveat of using DNA extracted from WBC is the relative
contributions made by the respective cell types [57], al-
though the overall impact of blood cell composition
across individuals is not considered to be substantial
[55]. Herein, CG methylation levels were comparable in
WBC, PBMC, and CD4+ T lymphocytes.
The molecular mechanisms that link CG methylation
of the P2 promoter and IGF1 gene expression are un-
known. In general, gene expression is regulated epige-
netically by DNA methylation, histone modifications,
and nucleosome positioning. The P2 promoter of IGF1
belongs to the category of non-CG island promoters,
more precisely to the family of low CG promoters,
where methylation is known to contribute to the regula-
tion of gene expression [58]. Despite the fact that 45% of
all human gene promoters, particularly those controlling
the expression of tissue-specific genes, do not lie within
CG islands [59], little is known about their regulation
and the potential role of methylation as a transcriptional
control mechanism [60]. Among the few studies that
have investigated the correlation between DNA methyla-
tion and expression of genes having non-CG island pro-
moters, the majority do not support the view that DNA
methylation directly leads to transcription silencing of
these genes [60]. A number of genes with non-CG island
promoters display a tissue-specific methylation pattern,
suggesting that CG methylation may play a role in the
establishment and maintenance of tissue-specific expres-
sion patterns [61]. Some studies have shown that there
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Figure 6 .The demethylation of the IGF1-P2 region increases
luciferase activity. Results of luciferase assays in transiently
transfected HEK293 cells. Forty-eight hours after transfection,
basal activity of unmethylated and methylated, Firefly luciferase
reporter plasmids containing IGF1 promoter 2 CG fragment, and
empty Firefly luciferase reporter plasmid, pCpGL-Basic, was measured,
and normalized to the activity of co-transfected Renilla luciferase
plasmid. Results were analyzed by paired t-test, **P < 10−4, and bars
represent three independent experiments (mean ± SEM).
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is an inverse correlation between methylation and gene
expression [61], whereas other studies have reported that
CG-poor promoters could be still expressed when they
are methylated [62]. However, when promoters were
categorized into low, intermediate, and high CG density,
it was found that the inverse correlation between methy-
lation and expression holds in promoters with low CG
density [63] and we suspect this could apply to the CG-
poor P2 promoter of the IGF1 gene.
To assess whether DNA methylation can directly regu-
late the P2 promoter, we utilized a CG-less luciferase-
gene containing vector to perform the luciferase reporter
assay. This CG-less vector overcomes the problems pre-
viously associated with testing methylation-sensitive pro-
moter activity in vitro, notably the existence of CG sites
in the coding region of the luciferase gene and vector
backbone, which potentially contributes to the repres-
sion of the promoter [64]. The Stat5b binding sites being
located outside of the transfected P2 promoter [65],
Stat5b could not contribute to the observed regulation
of gene expression in our transfection experiments.
These experiments demonstrate that DNA methylation
of the non-CG island P2 promoter of IGF1 can directly
silence gene expression, as previously shown when plas-
mid constructs containing the non-CG island promoters
of LAMB3 and RUNX3 genes were transfected into
HaCaT cells and 623 melanoma cells [60].
The main physiological regulator of IGF1 is GH. The
importance of epigenetic mechanisms in the regulation
of IGF1 gene expression by GH starts to be unraveled in
the liver of hypophysectomised rats, where GH induces
dramatic changes in chromatin at the IGF1 locus and ac-
tivates IGF1 transcription by distinct promoter-specific
epigenetic mechanisms [66,67]. The proximal part of rat
P2 is an important site of transcriptional regulation by
GH via Stat5b [65]. In the rat liver, GH induces rapid
and dramatic changes in chromatin at the P2 promoter
and activates IGF1 transcription by specific epigenetic
mechanisms [66,67]. At promoter P2, GH facilitates re-
cruitment then activation of RNA Pol II to initiate tran-
scription, whereas at promoter P1, GH causes RNA Pol
II to be released from a previously recruited poised and
paused pre-initiation complex [66]. CG locations are
different in human and rat IGF1 promoters, and the pat-
tern of methylation or transcriptional effects of these
CGs are unknown in rats. Taken together, our observa-
tions in human PBMC and transfected cells support that
P2 promoter methylation is a strong negative and direct
modulator of P2-driven transcription of the human IGF1
gene, through mechanisms that do not involve Stat5b
intervention.
Many questions are left unanswered by the present
study, including the epigenetic participation of the P2
promoter to the ‘missing heritability/causality’ of human
height variability [68,69] and to the phenotypic plasticity
of growth physiology [70]. Another potential application
of our finding comes from the pleiotropic role of IGF1
in many developmental and physiological or pathological
processes related to aging, longevity, energy metabolism,
brain functions, and cancer.
Conclusions
The P2 promoter of the IGF1 gene is a significant
QTLepi for skeletal growth and serum IGF1. The relation-
ship between P2 methylation and these growth-related
traits seems to be mediated by primary transcriptional ef-
fects taking place at the P2 promoter.
Methods
Participants
To explore the relation between IGF1 promoter methy-
lation and height, we recruited children who have not
yet entered puberty. Mean age was 9.7 years in boys and
9.6 in girls. Testosterone levels were lower than 0.1 ng/ml
in all boys, and no girl had any breast development at time
of study. This criterion of selection avoids the confound-
ing effect of the variable tempo of sexual maturation,
which adds to the variability of adolescent growth, adult
height, and serum IGF1. Our discovery cohort was formed
with 110 Caucasian white children (58 M/52 F) who had
been recruited by the EpiGrowth Consortium. They either
had a history of short stature or were control children of
various statures. For our replication cohort, we used
106 unrelated healthy white children (63 M/43 F) of
the GH-Pharmacogenetic Cohort, which include chil-
dren with short stature [71]. Children were all healthy,
had normal clinical examination and no signs of pu-
berty. GH deficiency was excluded with a stimulated
GH peak >15 ng/ml. All had normal TSH levels; subtle
chondrodysplasia were excluded by forearm, pelvis,
and spine radiographs.
Trained nurses performed height measurements in du-
plicate using the Harpenden stadiometer. Ten milliliters
of peripheral blood samples was obtained, from which
WBC and/or PBMC or CD4+ T lymphocytes were puri-
fied immediately. WBC and PBMC were counted at time
of sampling. Samples were obtained from liver and
growth plates of children undergoing surgical proce-
dures for reasons independent from the current study.
Parents gave written informed consent for the current
study and for using surgical specimens, according to the
French rules of bioethics in biomedical research. The re-
search protocol received the agreement of our Institutional
Review Board of Paris Sud University.
Serum IGF1 measurements
Serum IGF1 concentration was measured around 7.00 to
8.00 am before breakfast in 184/216 children using an
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immune-radiometric assay after ethanol-acid extraction
using DSL-5600 Active (Diagnostic System Laboratories,
Webster, TX, USA) or Cisbio reagents (Cisbio Inter-
national, Codolet, France). Intra- and inter-series coeffi-
cients of variation were 1.5% and 3.7% at 260 ng/ml and
3.9% at 760 ng/ml. The sensitivity was 4 ng/ml. IGF1
SDS were calculated using the norms of Alberti et al. in
French children [72].
Pyrosequencing-based bisulfite PCR analysis
For promoter P1, we studied 9 CGs located over a 800-
bp distance, the closest CG being 225 bp upstream from
the corresponding major TSS [73]. For promoter P2, we
studied 7/8 CGs located upstream from the major TSS
within the proximal part of the promoter and 1 CG lo-
cated 97 bp downstream this TSS. CGs are denominated
according to their position versus each promoter TSS
(Figure 1). The methylation of CG-22 could not be mea-
sured for technical reasons. Nucleic acids were extracted
from WBC or PBMC using Gentra Puregene blood kit
(Qiagen, Hilden, Germany). In a subset of 20 patients,
WBC and PBMC were measured in the same samples.
Methylation was measured in other patients using
PBMC. A bisulfite-PCR-pyrosequencing technique [74]
was used to measure the methylation of the CGs. We
improved the resolution of this method from a handful
of bases to up to 100 nucleotides, with the ability to
quantify methylation in the same sample of blood with a
coefficient of variation (SD/mean) as little as 1% to 5%.
Briefly, 400 nanograms of genomic DNA were treated
with EZ DNA Methylation-Gold Kit, according to
manufacturer’s protocol (Zymo Research Corporation,
Irvine, CA, USA). The bisulfite-treated genomic DNA
was PCR-amplified using unbiased IGF1 primers (see
Additional file 1: Table S1) and performed quantitative
pyrosequencing using a PyroMark Q96 ID Pyrose-
quencing instrument (Qiagen, Hilden, Germany). Py-
rosequencing assays were designed using MethPrimer
(http://www.urogene.org/methprimer/index1.html). Biotin-
labeled single-stranded amplicons were isolated according
to protocol using the Qiagen Pyromark Q96 Work Station
(Qiagen, Hilden, Germany) and underwent pyrose-
quencing with 0.5 μM primer. The percent methylation
for each of the CGs within the target sequence was cal-
culated using PyroQ CpG Software (Qiagen, Hilden,
Germany).
Liver and tibial growth plate samples were washed
with PBS and dissected to remove conjunctive tissue
and blood. The biopsies were ground in cell lysis solu-
tion (Qiagen, Hilden, Germany) with Minilys® (Bertin
Technologies, Montigny-le-Bretonneux) according to
manufacter’s recommendation. Nucleic acids were
extracted using Gentra Puregene tissue kit (Qiagen,
Hilden, Germany).
Study of IGF1 transcripts in PBMC
PBMC were almost immediately isolated from fresh
blood in 49 children using a density gradient. Four milli-
liters of fresh blood was mixed with 4 ml of NaCl 154
mM, and then, 4 ml of Lymphoprep solution (Eurobio,
Paris, France) was added to diluted blood and centri-
fuged for 20 min at room temperature at 800g. After
centrifugation, the interphase containing PBMC was
carefully aspirated and the cells were mixed with NaCl.
The cell suspension was centrifuged at 300g, and the cell
pellet washed with PBS before 700 μl of Qiazol (Qiagen,
Hilden, Germany) was added and the pellet frozen
in −80°C. Total RNA was isolated using miRNA mini kit
(Qiagen), according to manufacturer’s protocol. Genomic
DNA was removed using DNAse treatment. RNA integ-
rity was assessed by bioanalyser (Agilent 2100, Agilent
Technologies, Palo Alto, CA, USA) and expressed as RNA
integrity number (RIN) considered acceptable within the
range of 7 to 10. One microgram RNA was reverse-
transcribed with random hexamers and oligo(dT) in a
final volume of 18 μl using PrimeScript RT reagent kit
(TAKARA, Tokyo, Japan). Parallel reactions without re-
verse transcriptase enzyme were prepared as negative
controls.
qPCR for samples were prepared in triplicate and run
on ABI 7500 fast (Applied Biosystems, Foster City, CA,
USA). We amplified P1-driven, P2-driven, and whole
transcripts of IGF1 transcripts using predesigned Cus-
tom TaqMan gene expression assay (Integrated DNA
Technologies IDT, Coralville, IA, USA) (Additional file 1:
Table S1). To detect P1-driven transcripts, P2-driven tran-
scripts, and global IGF1 transcripts separately, TaqMan as-
says were derived respectively from exons 1 to 3, exons 2
to 3, and exons 3 to 4. We measured P1-driven tran-
scripts, P2-driven transcripts, and global transcripts of
IGF1 gene in PBMC using absolute quantification with an
external calibration curve model.
A calibration standard curve was established using a
cDNA clone containing qPCR product targeted by each
IGF1 TaqMan assay. A series of seven concentrations of
IGF1 cDNA clone was prepared by serial dilution. The
standard curves were constructed by plotting the cycle
threshold vs. the concentration of DNA (log10 scale).
The equation, slope, and correlation coefficient for each
curve are presented in Additional file 2: Figure S1.
Construction of the reporter gene plasmid
Fragment of human IGF1-P2, −1,014 to +64, including
CGs located within the proximal part of the promoter 2,
was PCR amplified from the human genomic DNA using
SpeI restriction site added forward primer (Additional
file 1: Table S1) and NcoI restriction site added reverse
primer with Phusion High-Fidelity DNA Polymerase
(Thermo Fisher Scientific, Waltham, MA, USA). PCR
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product cloned into upstream of the firefly luciferase
gene in the promoter-less CpG-free pCpGL-Basic vector
(gift from Rehli’s Lab, Regensburg, Germany) between
SpeI-NcoI sites and transformed into PIR1 competent
cells (Invitrogen, Carlsbad, CA, USA) for plasmid
production.
In vitro methylation protocol was adapted from Klug
and Rehli [64]. IGF1-P2, −1,014 to +64, in pCpGL-Basic
was incubated at 37°C for 6 h with M.SssI CpG Methyl-
transferase (New England Biolabs, Ipswich, MA, USA)
(2.5 U/μg DNA), in the presence of a methyl group
donor 160 μM S-adenosylmethionine (SAM). One hun-
dred sixty micromolar SAM was added every 2 h during
incubation. Unmethylated plasmid was treated as above
but without the M.SssI CpG Methyltransferase. Plasmid
DNA was phenol/chloroform extracted and ethanol pre-
cipitated and quantified using a NanoDrop Spectropho-
tometer (ND-1000, NanoDrop Technologies, Wilmington,
DE, USA). The completeness of the methylation for both
methylated and unmethylated plasmids were first con-
firmed with methylation-sensitive restriction enzyme
HpaII and methylation-insensitive (MspI) restriction
enzyme.
Cell culture, transient transfection, and luciferase reporter
assays
Human embryonic kidney 293 (HEK293) cell line
(American Type Culture Collection (ATCC)) was
maintained in Dulbecco’s Modified Eagle’s medium
(DMEM; Life Technologies, Carlsbad, CA, USA) sup-
plemented with 10% fetal bovine serum (HyClone,
Thermo Fisher Scientific, Waltham, MA, USA), peni-
cillin/streptomycin, and glutamine (PAA Laboratories,
Pashing, Austria). Cells were maintained at 37°C in a
humidified atmosphere containing 95% air and 5% CO2.
HEK293 cells in 96-well plates were co-transfected using
X-tremeGENE HP DNA Transfection Reagent (Roche, In-
dianapolis, IN, USA) with 80 ng/well methylated or
unmethylated promoter-less CpG-free Firefly Luciferase
expressing plasmid containing IGF1-P2 fragment with the
8 studied CGs, and 1 ng/well pRL-TK expressing plasmid
(Promega, Madison, WI, USA), containing a constitutively
expressed Renilla luciferase reporter gene used as an in-
ternal control for transfection efficiency. Luminescence
was measured 48 h after transfection using dual-luciferase
reporter assay system (Promega, Madison, WI, USA), and
Centro LB 960 luminometer (Berthold Technologies, Oak
Ridge, TN, USA). Results from three independent trans-
fection experiments were averaged for comparison.
Genotyping distribution of (CA)n IGF1 repeat
Genotyping of the IGF1 gene repeats, located 1 kb up-
steam from the major P1 transcription start site, was
adapted from Cleveland et al. [75] and Arends et al. [76]
protocols. PCR were carried out in 25-μl volumes with
30 ng of genomic DNA using 2 μM of each primer (see
Additional file 1: Table S1), 100 μM dNTPs, 1.5 mM
MgCl2 25 mM, 2.5 μl of the manufacturer’s standard
buffer and 1U of Taq RED polymerase (Eurogentec,
Angers). Samples were processed through one cycle of 3
min at 94°C, 35 temperature cycles consisting of 30 s at
94°C (denaturation), 30 s at 55°C (annealing), and 30 s at
72°C (elongation), with the last elongation step length-
ened to 10 min. The forward primer was 5′labeled with
FAM fluorescent dye for automated fragment analysis
(ABI Applied Biosystems, Foster City, CA, USA). The
PCR amplified products were diluted 1/10, and 1 μl of
the diluted PCR product is added to 10 μl of formamide
mix and 0.5 μl of Gen Scan 500 marquer. GeneMapper
4 was used to analyzed the length of samples.
Calculations and statistical methods
IGF1 levels and height were expressed as SDS to adjust
for age and sex. Pearson correlations were calculated as
adjusted R-squared. The fraction of explained variance
across children was calculated under the linear regression
model, using the usual definition: r2 × 100. Wilcoxon rank
tests and unpaired Student’s t-tests were both used to
compare methylation levels in studied tissues and the re-
sults of transfections with the demethylated or methylated
P2 promoter. The Bonferroni correction was used to ac-
count for the number of CG tested. All statistics were
computed using R 2.10.1. The results are expressed as
mean ± SD.
Additional files
Additional file 1: List of primers used in our study. Sequences are
given from 5to 3′.
Additional file 2: Standard curves used for the measurement of
IGF1 gene transcript content in PBMC.
Abbreviations
IGF1: insulin-like growth factor 1; PBMC: peripheral blood mononuclear cells;
QTL: quantitative trait locus; QTLepi: epigenetic quantitative trait locus;
WBC: whole blood cells..
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PB designed the study, recruited the patients, interpreted the data, and
wrote the manuscript. MO did the experiments and interpreted the results.
YG did the plasmid experiment. MPB studied the P1 promoter. DF
supervised the pyrosequencing platform. All authors read and approved the
final manuscript.
Acknowledgements
We thank Rehli’s lab for the gift of the promoter-less vector used in the
reporter gene assay experiment. Pfizer France supported this project with
research grants. MO is a doctoral fellow at Paris Descartes doctoral school.
MPB was supported by the Association de Recherche sur le Diabète.
Ouni et al. Clinical Epigenetics  (2015) 7:22 Page 10 of 12
Received: 1 December 2014 Accepted: 19 February 2015
References
1. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, et al. Consensus
statement on the diagnosis and treatment of children with idiopathic short
stature: a summary of the Growth Hormone Research Society, the Lawson
Wilkins Pediatric Endocrine Society, and the European Society for Paediatric
Endocrinology Workshop. J Clin Endocrinol Metab. 2007;2008(93):4210–7.
2. Rosenfeld RG. The molecular basis of idiopathic short stature. Growth Horm
IGF Res. 2005;15(Suppl A):S3–5.
3. Cole TJ. The secular trend in human physical growth: a biological view.
Econ Hum Biol. 2003;1:161–8.
4. Galton F, Dickson JDH. Family likeness in stature. Proc R Soc Lond.
1886;40:42–73.
5. Visscher PM, McEvoy B, Yang J. From Galton to GWAS: quantitative genetics
of human height. Genet Res. 2010;92:371–9.
6. Hirschhorn JN, Gajdos ZKZ. Genome-wide association studies: results from
the first few years and potential implications for clinical medicine. Annu Rev
Med. 2011;62:11–24.
7. Fisher RA. XV. - The correlation between relatives on the supposition of
Mendelian inheritance. Earth Environ Sci Trans R Soc Edinb.
1919;52:399–433.
8. Silventoinen K, Sammalisto S, Perola M, Boomsma DI, Cornes BK, Davis C,
et al. Heritability of adult body height: a comparative study of twin cohorts
in eight countries. Twin Res. 2003;6:399–408.
9. Wood AR, Esko T, Yang J, Vedantam S, Pers TH, Gustafsson S, et al. Defining
the role of common variation in the genomic and biological architecture of
adult human height. Nat Genet. 2014;46:1173–86.
10. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Rivadeneira F,
et al. Hundreds of variants clustered in genomic loci and biological
pathways affect human height. Nature. 2010;467:832–8.
11. Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, Nyholt DR, et al.
Common SNPs explain a large proportion of the heritability for human
height. Nat Genet. 2010;42:565–9.
12. Murrell A, Rakyan VK, Beck S. From genome to epigenome. Hum Mol Genet.
2005;14(Spec No 1):R3–10.
13. Johannes F, Colot V, Jansen RC. Epigenome dynamics: a quantitative
genetics perspective. Nat Rev Genet. 2008;9:883–90.
14. Rakyan VK, Down TA, Balding DJ, Beck S. Epigenome-wide association
studies for common human diseases. Nat Rev Genet. 2011;12:529–41.
15. Woods KA, Camacho-Hübner C, Savage MO, Clark AJ. Intrauterine growth
retardation and postnatal growth failure associated with deletion of the
insulin-like growth factor I gene. N Engl J Med. 1996;335:1363–7.
16. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth
hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev
Biol. 2001;229:141–62.
17. Rogers I, Metcalfe C, Gunnell D, Emmett P, Dunger D, Holly J, et al. Insulin-like
growth factor-I and growth in height, leg length, and trunk length between
ages 5 and 10 years. J Clin Endocrinol Metab. 2006;91:2514–9.
18. Cohen P. Controversy in clinical endocrinology: problems with reclassification
of insulin-like growth factor I production and action disorders. J Clin Endocrinol
Metab. 2006;91:4235–6.
19. Frayling TM, Hattersley AT, McCarthy A, Holly J, Mitchell SMS, Gloyn AL,
et al. A putative functional polymorphism in the IGF-I gene association
studies with type 2 diabetes, adult height, glucose tolerance, and fetal
growth in U.K. Populations. Diabetes. 2002;51:2313–6.
20. Lettre G, Butler JL, Ardlie KG, Hirschhorn JN. Common genetic variation in
eight genes of the GH/IGF1 axis does not contribute to adult height
variation. Hum Genet. 2007;122:129–39.
21. Kim J-J, Lee H-I, Park T, Kim K, Lee J-E, Cho NH, et al. Identification of 15 loci
influencing height in a Korean population. J Hum Genet. 2009;55:27–31.
22. Okada Y, Kamatani Y, Takahashi A, Matsuda K, Hosono N, Ohmiya H, et al. A
genome-wide association study in 19 633 Japanese subjects identified
LHX3-QSOX2 and IGF1 as adult height loci. Hum Mol Genet.
2010;19:2303–12.
23. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, et al.
Genetic and environmental components of interindividual variation in
circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest.
1996;98:2612–5.
24. Kao PC, Matheny AP, Lang CA. Insulin-like growth factor-I comparisons in
healthy twin children. J Clin Endocrinol Metab. 1994;78:310–2.
25. Verhaeghe J, Loos R, Vlietinck R, Van Herck E, van Bree R, DSchutter AM.
C-peptide, insulin-like growth factors I and II, and insulin-like growth factor
binding protein-1 in cord serum of twins: genetic versus environmental
regulation. Am J Obstet Gynecol. 1996;175:1180–8.
26. Palles C, Johnson N, Coupland B, Taylor C, Carvajal J, Holly J, et al.
Identification of genetic variants that influence circulating IGF1 levels: a
targeted search strategy. Hum Mol Genet. 2008;17:1457–64.
27. Al-Zahrani A, Sandhu MS, Luben RN, Thompson D, Baynes C, Pooley KA,
et al. IGF1 and IGFBP3 tagging polymorphisms are associated with
circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet.
2006;15:1–10.
28. Wong H-L, DeLellis K, Probst-Hensch N, Koh W-P, Berg DVD, Lee H-P, et al. A
new single nucleotide polymorphism in the insulin-like growth factor I
regulatory region associates with colorectal cancer risk in Singapore
Chinese. Cancer Epidemiol Biomarkers Prev. 2005;14:144–51.
29. Ester WA, Hokken-Koelega ACS. Polymorphisms in the IGF1 and IGF1R genes
and children born small for gestational age: results of large population
studies. Best Pract Res Clin Endocrinol Metab. 2008;22:415–31.
30. Vaessen N, Janssen JA, Heutink P, Hofman A, Lamberts SWJ, Oostra BA, et al.
Association between genetic variation in the gene for insulin-like growth
factor-I and low birthweight. Lancet. 2002;359:1036–7.
31. Rotwein P. Mapping the growth hormone - Stat5b - IGF-I transcriptional
circuit. Trends Endocrinol Metab. 2012;23:186–93.
32. Bock C, Walter J, Paulsen M, Lengauer T. Inter-individual variation of DNA
methylation and its implications for large-scale epigenome mapping.
Nucleic Acids Res. 2008;36:e55.
33. Kuroda A, Rauch TA, Todorov I, Ku HT, Al-Abdullah IH, Kandeel F, et al.
Insulin gene expression is regulated by DNA methylation. PLoS ONE.
2009;4:e6953.
34. Murgatroyd C, Patchev AV, Wu Y, Micale V, Bockmühl Y, Fischer D, et al.
Dynamic DNA methylation programs persistent adverse effects of early-life
stress. Nat Neurosci. 2009;12:1559–66.
35. Yang H, Adamo ML, Koval AP, McGuinness MC, Ben-Hur H, Yang Y, et al.
Alternative leader sequences in insulin-like growth factor I mRNAs modulate
translational efficiency and encode multiple signal peptides. Mol Endocrinol.
1995;9:1380–95.
36. Adamo ML, Ben-Hur H, Roberts CT, LeRoith D. Regulation of start site usage
in the leader exons of the rat insulin-like growth factor-I gene by
development, fasting, and diabetes. Mol Endocrinol. 1991;5:1677–86.
37. Oberbauer AM. The regulation of IGF-1 gene transcription and splicing
during development and aging. Front Endocrinol. 2013;4:39.
38. Weedon MN, Lettre G, Freathy RM, Lindgren CM, Voight BF, Perry JRB, et al.
A common variant of HMGA2 is associated with adult and childhood
height in the general population. Nat Genet. 2007;39:1245–50.
39. Sanna S, Jackson AU, Nagaraja R, Willer CJ, Chen W-M, Bonnycastle LL, et al.
Common variants in the GDF5-UQCC region are associated with variation in
human height. Nat Genet. 2008;40:198–203.
40. Weedon MN, Lango H, Lindgren CM, Wallace C, Evans DM, Mangino M,
et al. Genome-wide association analysis identifies 20 loci that influence
adult height. Nat Genet. 2008;40:575–83.
41. Bogin B. Secular changes in childhood, adolescent and adult stature. Nestlé
Nutr Inst Workshop Ser. 2013;71:115–26.
42. Clemmons DR, Underwood LE. Nutritional regulation of IGF-I and IGF binding
proteins. Annu Rev Nutr. 1991;11:393–412.
43. Bird A. Putting the DNA back into DNA methylation. Nat Genet.
2011;43:1050–1.
44. Knight JC. Allele-specific gene expression uncovered. Trends Genet TIG.
2004;20:113–6.
45. Meaburn EL, Schalkwyk LC, Mill J. Allele-specific methylation in the human
genome: implications for genetic studies of complex disease. Epigenetics.
2010;5:578–82.
46. Fradin D, Le Fur S, Mille C, Naoui N, Groves C, Zelenika D, et al. Association
of the CpG methylation pattern of the proximal insulin gene promoter with
type 1 diabetes. PLoS ONE. 2012;7:e36278.
47. Richards EJ. Population epigenetics. Curr Opin Genet Dev. 2008;18:221–6
[Chromosomes and Expression Mechanisms].
48. Bell JT, Pai AA, Pickrell JK, Gaffney DJ, Pique-Regi R, Degner JF, et al. DNA
methylation patterns associate with genetic and gene expression variation
in HapMap cell lines. Genome Biol. 2011;12:R10.
Ouni et al. Clinical Epigenetics  (2015) 7:22 Page 11 of 12
49. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, et al.
Epigenetic differences arise during the lifetime of monozygotic twins. Proc
Natl Acad Sci U S A. 2005;102:10604–9.
50. Kaminsky ZA, Tang T, Wang S-C, Ptak C, Oh GHT, Wong AHC, et al. DNA
methylation profiles in monozygotic and dizygotic twins. Nat Genet.
2009;41:240–5.
51. Petronis A. Epigenetics and twins: three variations on the theme. Trends
Genet TIG. 2006;22:347–50.
52. Yakar S, Pennisi P, Wu Y, Zhao H, LeRoith D. Clinical relevance of systemic
and local IGF-I. In: Cianfarani S, Clemmons DR, Savage MO, editors.
Endocrine Development. Basel: KARGER; 2005. p. 11–6.
53. Liu JL, Yakar S, LeRoith D. Conditional knockout of mouse insulin-like
growth factor-1 gene using the Cre/loxP system. Proc Soc Exp Biol Med.
2000;223:344–51.
54. Feinberg AP, Irizarry RA, Fradin D, Aryee MJ, Murakami P, Aspelund T, et al.
Personalized epigenomic signatures that are stable over time and covary
with body mass index. Sci Transl Med. 2010;2:49ra67.
55. Talens RP, Boomsma DI, Tobi EW, Kremer D, Jukema JW, Willemsen G, et al.
Variation, patterns, and temporal stability of DNA methylation:
considerations for epigenetic epidemiology. FASEB J. 2010;24:3135–44.
56. Mill J, Heijmans BT. From promises to practical strategies in epigenetic
epidemiology. Nat Rev Genet. 2013;14:585–94.
57. Wu H-C, Delgado-Cruzata L, Flom JD, Kappil M, Ferris JS, Liao Y, et al. Global
methylation profiles in DNA from different blood cell types. Epigenetics.
2011;6:76–85.
58. Xie W, Schultz MD, Lister R, Hou Z, Rajagopal N, Ray P, et al. Epigenomic
analysis of multilineage differentiation of human embryonic stem cells. Cell.
2013;153:1134–48.
59. Takai D, Jones PA. Comprehensive analysis of CpG islands in human
chromosomes 21 and 22. Proc Natl Acad Sci U S A. 2002;99:3740–5.
60. Han H, Cortez CC, Yang X, Nichols PW, Jones PA, Liang G. DNA methylation
directly silences genes with non-CpG island promoters and establishes a
nucleosome occupied promoter. Hum Mol Genet. 2011;20:4299–310.
61. Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, Burger M, et al. DNA
methylation profiling of human chromosomes 6, 20 and 22. Nat Genet.
2006;38:1378–85.
62. Weber M, Hellmann I, Stadler MB, Ramos L, Pääbo S, Rebhan M, et al.
Distribution, silencing potential and evolutionary impact of promoter DNA
methylation in the human genome. Nat Genet. 2007;39:457–66.
63. Gal-Yam EN, Egger G, Iniguez L, Holster H, Einarsson S, Zhang X, et al.
Frequent switching of polycomb repressive marks and DNA
hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci
U S A. 2008;105:12979–84.
64. Klug M, Rehli M. Functional analysis of promoter CpG methylation using a
CpG-free luciferase reporter vector. Epigenetics. 2006;1:127–30.
65. Varco-Merth B, Mirza K, Alzhanov DT, Chia DJ, Rotwein P. Biochemical
characterization of diverse Stat5b-binding enhancers that mediate growth
hormone-activated insulin-like growth factor-I gene transcription. PLoS ONE.
2012;7:e50278.
66. Chia DJ, Young JJ, Mertens AR, Rotwein P. Distinct alterations in chromatin
organization of the two IGF-I promoters precede growth hormone-induced
activation of IGF-I gene transcription. Mol Endocrinol. 2010;24:779–89.
67. Chia DJ, Rotwein P. Defining the epigenetic actions of growth hormone:
acute chromatin changes accompany GH-activated gene transcription. Mol
Endocrinol. 2010;24:2038–49.
68. Slatkin M. Epigenetic inheritance and the missing heritability problem.
Genetics. 2009;182:845–50.
69. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al.
Finding the missing heritability of complex diseases. Nature.
2009;461:747–53.
70. Atchley WR, Zhu J. Developmental quantitative genetics, conditional
epigenetic variability and growth in mice. Genetics. 1997;147:765–76.
71. Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougnères P. A
common polymorphism of the growth hormone receptor is associated with
increased responsiveness to growth hormone. Nat Genet. 2004;36:720–4.
72. Alberti C, Chevenne D, Mercat I, Josserand E, Armoogum-Boizeau P, Tichet J,
et al. Serum concentrations of insulin-like growth factor (IGF)-1 and IGF
binding protein-3 (IGFBP-3), IGF-1/IGFBP-3 ratio, and markers of bone
turnover: reference values for French children and adolescents and z-score
comparability with other references. Clin Chem. 2011;57:1424–35.
73. Jansen E, Steenbergh PH, LeRoith D, Roberts CT, Sussenbach JS.
Identification of multiple transcription start sites in the human insulin-like
growth factor-I gene. Mol Cell Endocrinol. 1991;78:115–25.
74. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc.
2007;2:2265–75.
75. Cleveland RJ, Gammon MD, Edmiston SN, Teitelbaum SL, Britton JA, Terry
MB, et al. IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer
risk in the Long Island Breast Cancer Study Project. Carcinogenesis.
2006;27:758–65.
76. Arends N, Johnston L, Hokken-Koelega A, van Duijn C, de Ridder M, Savage
M, et al. Polymorphism in the IGF-I gene: clinical relevance for short children
born small for gestational age (SGA). J Clin Endocrinol Metab. 2002;87:2720.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ouni et al. Clinical Epigenetics  (2015) 7:22 Page 12 of 12
